Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
Inhibitors of epidermal growth factor receptor (EGFR) are commonly used as therapeutic agents in oncology. In contrast to currently used oncological treatments, these inhibitors almost always cause skin- and skin adnex toxicity. About 85% of treated patients develop to a more or lesser extent an acneiform eruption. Xerosis cutis and painful nail disorders occur in, respectively, 35% and 10-15% of all treated patients. Also hair and mucosal changes have been reported, although to a lesser extent. These skin- and skin adnex toxicities are reversible after withdrawal of treatment, but are seldom a reason to stop or interrupt therapy. This review outlines the classification, the pathogenesis and therapy of these skin, hair, nail and mucosal changes due to EGFR inhibition. Informing the patient and management of these side-effects is very important to reduce discomfort and as such to increase compliance to therapy.
Galimont-Collen
A F S
AF
Department of Dermatology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. a.f.s.collen@lumc.nl
Vos
L E
LE
Lavrijsen
A P M
AP
Ouwerkerk
J
J
Gelderblom
H
H
D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000628:therapy; D003875:Drug Eruptions / Q000145:classification* / Q000628:therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006201:Hair Diseases / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D009092:Mucous Membrane / Q000187:drug effects; D009260:Nail Diseases / Q000139:chemically induced* / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy*
D066246:ErbB Receptors